変異種対応版頑張ってもらいたいよなあ

 

buveryさんがリツイート

アストラゼネカのワクチン、南アフリカでの試験結果がついにNEJMに掲載。中間解析が以前公開されていましたが、J&Jやノババックスに比べると変異株により効果激減です
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Shabir A. Madhi et al.https://t.co/PTSlZKtmrR pic.twitter.com/TBNis1VexQ

— けんもう新型コロナ対策本部 (@kenmomd) March 17, 2021

これは以前から言われていたが、問題は重症予防になるかだね。 

AstraZeneca Vax Flops Against South African Variant in Early Trial

— But jury still out as to whether it prevents severe disease from the variant

by Molly Walker, Associate Editor, MedPage Today March 16, 2021

Madhi's group also noted there were no cases of hospitalization due to severe COVID-19 in either group, but because of participants' demographic and clinical profile, "the trial findings are inconclusive" with regards to whether or not the vaccine protects against severe disease from the B.1.351 variant.

まだ、はっきりしないらしい。

17-MAR-2021

South African Oxford AstraZeneca Covid-19 vaccine study a global game-changer

Peer review and publication validates findings and makes a compelling case for development of a second-generation vaccines worldwide.

Based on a broader body of evidence, the World Health Organization recommends that this vaccine still be deployed in countries where the B.1.351 variant circulates, as it likely still protects against severe infection, hospitalisation, and death caused by Covid-19.

 こちらの記事では、重症予防にはなるだろう、と言われているが、

Second-generation vaccine innovation

The development of an Oxford AstraZeneca and other Covid-19 vaccines targeting the B.1351 variant is currently underway.

対変異種対応版も開発中である、と。

頑張ってもらいたいよなあ。